Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.

TSX:EDT - Post by User

Spectral Medical Inc

Bullboard Posts

Comment by Inca2020on Jul 08, 2020 12:06pm

107 Views

Post# 31239747

RE:RE:RE:RE:RE:RE:Fair Share Value for PMX from Prospectus

All your number crunching isn't going to give them FDA approval or a US listing. Or is it going to make it any more sane that you have 5 aliases talking to one another.

mercedesman wrote:

Forgot to mention

analysts usually go through a discount process wherein they use a discount factor to discount cash flows each year ( back to a present value)
for example if it took them say 5 years to reach a 40% market penetration that would be reflected in the sum of all present values by year.

Rough rule of thumb, take 50% off your EBITDA valuations to reflect this time value of money factor.

Bottom-line....59 cents Cdn might be more representative of eventual / potential earnings per share rather than fair value per share of the Co today.

MM